Product Information
EMGALITY 120 MG/ML SYRINGE is a brand product labeled by Eli Lilly and Company, priced at $734.4208 per ML under NDC 00002237711. Its NADAC has been published 385 times since May 22, 2019.
Strength
120 mg/mL
Manufacturer
Eli Lilly and CompanyNDC
00002237711
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GALCANEZUMABApproval Type
Biologic (BLA)
FDA Application
BLA761063On Market Since
9/27/2018
Price Statistics
The NADAC for EMGALITY 120 MG/ML SYRINGE has been published 385 times since May 22, 2019, and over the history we have for it it has risen 31.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $734.4208 per ML |
|---|---|
| All-time high | $734.8506 (May 13, 2026) |
| All-time low | $553.7411 (Aug 21, 2019) |
| 52-week high | $734.8506 |
| 52-week low | $713.4472 |
| Median price | $656.1251 |
| Average price | $646.2345 |
| Largest weekly change | +5.0% (Jan 8, 2025) |
| Weeks tracked | 385 |
| Tracking since | May 22, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
galcanezumab-gnlm market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EMGALITY 120 MG/ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for EMGALITY 120 MG/ML SYRINGE, manufactured by Eli Lilly and Company, is $734.4208 per ML (NDC 00002237711), effective Sep 30, 2026.
How has the price of EMGALITY 120 MG/ML SYRINGE changed over time?
Over the history we have for it, the NADAC for EMGALITY 120 MG/ML SYRINGE has risen 31.1%. It has been tracked across 385 weekly CMS publications since May 22, 2019.
What are the highest and lowest recorded NADAC prices for EMGALITY 120 MG/ML SYRINGE?
Since May 22, 2019, the NADAC for EMGALITY 120 MG/ML SYRINGE has ranged from a low of $553.7411 (Aug 21, 2019) to a high of $734.8506 (May 13, 2026), with a median of $656.1251 per ML.
Are there cheaper alternatives to EMGALITY 120 MG/ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EMGALITY 120 MG/ML PEN, is $734.2833 per ML — about 0% below EMGALITY 120 MG/ML SYRINGE.
Who manufactures EMGALITY 120 MG/ML SYRINGE?
EMGALITY 120 MG/ML SYRINGE (NDC 00002237711) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.